AstraZeneca and the world according to GARP
AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, stands as a quintessential example of a 'growth at a reasonable price' (GARP) investment opportunity, according to Bank of America...
AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why
JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its t...
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
AstraZeneca CEO says they've reduced emissions by 60%
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & a...
AstraZeneca discontinues phase III trials
AstraZeneca PLC (LSE:AZN) has announced the discontinuation of two phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, for its drug Lokelma (sodium zirconium cyclosilicate). This decision stems f...
AstraZeneca to scrap two trials on drug that curbs potassium
AstraZeneca on Friday said it would discontinue two late-stage trials looking at the potential benefits of its drug Lokelma in the management of hyperkalaemia across the cardiorenal spectrum.
AstraZeneca needs margin clarity for further upside says Jefferies
AstraZeneca PLC (LSE:AZN) fell 0.9% as analysts at Jefferies trimmed estimates and argued that clarity on margins may be needed for further stock upside. The broker, has a buy rating on the Anglo-...
3 No-Brainer Stocks to Buy With $1,000 Right Now
Wall Street's major indexes have bounced back and forth between bull and bear markets over the past four years. Volatility invites opportunity for long-term-minded investors.
5 Growth Stocks to Buy for 2024
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
AstraZeneca: Leading bank tells us why the stock is a core holding
Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)'s shares, recommending an "overweight" position with a target price of £135, a significant premium to the current m...
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case.
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials.
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.
AstraZeneca gets US sign-off for breast cancer combination
AstraZeneca PLC (LSE:AZN) has secured US approval for a new breast cancer treatment, Truqap (capivasertib), to be used in combination with Faslodex (fulvestrant). It brings hope for a specific grou...
Related Companies